ICU · Renal / RRT
CRRT — Circuit, Prescription, Anticoagulation & Troubleshooting
Also known as Continuous renal replacement therapy · CRRT circuit · CRRT prescription · CRRT anticoagulation · Citrate anticoagulation · Regional citrate · Filtration fraction · Pre-dilution · Post-dilution · CRRT troubleshooting · Circuit clotting · Access pressure · Transmembrane pressure
The CRRT is delivered through a blood circuit — the dual-lumen central access, the blood pump, the pre-dilution (the replacement fluid before the filter), the haemofilter (the hollow-fibre membrane), the post-dilution (the replacement fluid after the filter), the air-trap, and the return. The pressures (the access negative, the return positive, the filter transmembrane) monitor the circuit patency and the clotting. The prescription: the modality (the CVVH, the CVVHDF), the dose (the effluent 20 to 25 mL/kg/h), the blood flow, the fluid balance, the fluid composition, and the anticoagulation. The anticoagulation is the regional citrate (the preferred; the post-filter ionized calcium 0.25 to 0.35 mmol/L; the total-to-ionized ratio under 2.5; the risks the metabolic alkalosis, the acidosis in the liver failure, the hypercalcaemia) or the heparin or none. The troubleshooting: the circuit clotting (the inadequate anticoagulation, the high filtration fraction, the low blood flow), the high access pressure (the catheter kink or the position), the air-in-line, and the electrolyte and the nutrient loss (replace the K, the phosphate, the Mg, the increased nutrition).
Checked against its sources on 2 Sept 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Overview — the four questions of every circuit
A CRRT circuit is plumbing, and your job is to keep it patent and delivering. Four questions run the bedside: is the circuit flowing, is the prescription right, is the anticoagulation holding, and why did it clot. Answer those four and you hold the whole topic.[16]
Continuous renal replacement therapy runs at the bedside around the clock, clearing solute and water slowly enough to keep the haemodynamics stable. The price of that gentleness is a circuit that clots — and the craft is keeping it running.[16]
References44ShowHide
- [1]Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial Nephrol Dial Transplant, 2011.PMID 20876598
- [2]Monchi M, Berghmans D, Ledoux D, et al Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study Intensive Care Med, 2004.PMID 14600809
- [3]Tsujimoto H, Tsujimoto Y, Nakata Y, et al Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy Cochrane Database Syst Rev, 2020.PMID 32164041
- [4]Oudemans-van Straaten HM Citrate anticoagulation for continuous venovenous hemofiltration Crit Care Med, 2009.PMID 19114912
- [5]Legrand M, Tolwani A Anticoagulation strategies in continuous renal replacement therapy Semin Dial, 2021.PMID 33684244
- [6]Bianchi NA, Altarelli M, Schneider AG Complications of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: An Observational Study Blood Purif, 2020.PMID 32126564
- [7]Lameire N, Kellum JA Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2) Crit Care, 2013.PMID 23394215
- [8]Wald R, Beaubien-Souligny W, Chanchlani R, et al. Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury Intensive Care Med, 2022.PMID 36066597
- [9]Warkentin TE Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia: Too Good to Be True? J Am Coll Cardiol, 2017.PMID 29169471
- [10]Zhang W, Chen X, Chen Y, et al. Clinical experience with nadroparin in patients undergoing dialysis for renal impairment Hemodial Int, 2011.PMID 21722301
- [11]Arcangeli A, Rocca B, Salvatori G, et al. Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter Thromb Res, 2010.PMID 20185164
- [12]Kozek-Langenecker SA, Spiss CK, Gamsjäger T, et al. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial Wien Klin Wochenschr, 2002.PMID 12060975
- [13]Langenecker SA, Felfernig M, Werba A, et al Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration Crit Care Med, 1994.PMID 7956281
- [14]Wang W, Zhao J, Zhang X, et al. Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk: A Meta-Analysis Systemic Review Kidney Dis (Basel), 2026.PMID 41909499
- [15]Chen Y, Feng F, Li Q, et al. Safety and effectiveness of nafamostat mesylate in continuous renal replacement therapy in patients with sepsis-associated acute kidney injury: a prospective randomized controlled trial Open Med (Wars), 2026.PMID 41737413
- [16]Dai T, Shah A, Chong CC, et al. Evolution of continuous renal replacement therapy scenarios and the rise of anticoagulant-free continuous veno-venous hemodiafiltration Curr Opin Nephrol Hypertens, 2026.PMID 41263052
- [17]Rhee H, Berenger B, Mehta RL, et al. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study Am J Kidney Dis, 2021.PMID 33798636
- [18]Vinsonneau C, Allain-Launay E, Blayau C, et al. Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD) Ann Intensive Care, 2015.PMID 26714808
- [19]Fabbri LP, Nucera M, Becchi P, et al Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study Acta Anaesthesiol Scand, 2010.PMID 19650808
- [20]Bellomo R, Cass A, Cole L, Finfer S, et al. Intensity of continuous renal-replacement therapy in critically ill patients N Engl J Med, 2009.PMID 19846848
- [21]Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, et al. Intensity of renal support in critically ill patients with acute kidney injury N Engl J Med, 2008.PMID 18492867
- [22]Oudemans-van Straaten HM, Ostermann M Citrate anticoagulation for CRRT: don't always trust the postfilter iCa results! Crit Care, 2015.PMID 26635277
- [23]Assefi M, Leurent A, Blanchard F, Quemeneur C, et al. Impact of increasing post-filter ionized calcium target on filter lifespan in renal replacement therapy with regional citrate anticoagulation: A before-and-after study J Crit Care, 2023.PMID 37379797
- [24]Assefi M, Braik R, James A, Clavieras N, et al. Impact of increasing post-filter ionised calcium target on regional citrate anticoagulation efficacy in ICU continuous renal replacement therapy: the non-inferiority randomised controlled Ca-CIBLE protocol BMJ Open, 2024.PMID 39327056
- [25]Schultheiß C, Saugel B, Phillip V, Thies P, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Crit Care, 2012.PMID 22913794
- [26]Zhang W, Bai M, Yu Y, Li L, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis Crit Care, 2019.PMID 30678706
- [27]Wang F, Lin L, Li P, Huang X, et al. Saline flushing to prevent circuit clotting during CRRT without anticoagulant: a randomized controlled study BMC Nurs, 2025.PMID 40855484
- [28]Cuker A, Gimotty PA, Crowther MA, Warkentin TE, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis Blood, 2012.PMID 22990018
- [29]Ampatzidou F, Argyriadou E, Amaniti C, Sarridou D, et al. Postoperative Thrombocytopenia in Cardiac Surgery: Patterns, Differential Diagnosis and Management of Heparin-Induced Thrombocytopenia J Clin Med, 2025.PMID 41464670
- [30]Capuano I, Riccio E, Buonanno P, Tufano A, et al. Heparin-induced thrombocytopenia: a challenging diagnosis in haemodialysis-state of art and review of the literature Clin Kidney J, 2026.PMID 42111239
- [31]Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia Circulation, 2001.PMID 11294800
- [32]Sinatra N, Cuttone G, Geraci G, Carollo C, et al. Correlation Between Hypophosphatemia and Hyperventilation in Critically Ill Patients: Causes, Clinical Manifestations, and Management Strategies Biomedicines, 2025.PMID 41153669
- [33]Li P, Li M, Yin W, Zhou Z, et al. Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial BMC Nephrol, 2025.PMID 41199170
- [34]Dimski T, Brandenburger T, Vollmer C, Kindgen-Milles D, et al. A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation BMC Nephrol, 2024.PMID 38982339
- [35]Toprak HB, Taşkın G, Bayrak MA, Sallan M, et al. Real-World Safety and Circuit Outcomes of Protocolized Divided-Dose Enoxaparin During Continuous Renal Replacement Therapy Without Routine Anti-Xa Monitoring: A Single-Center Competing-Risk Cohort Study J Clin Med, 2026.PMID 42513259
- [36]Rhee H, Jung KS, Ku EY Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy Sci Rep, 2026.PMID 42477433
- [37]Zeng X, Cai X, Liao Z, Xiao Y, et al. Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety Ren Fail, 2025.PMID 41188191
- [38]Boer W, Verbrugghe W, Hoste E, Jacobs R, et al. Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review Ann Intensive Care, 2023.PMID 36899104
- [39]Yessayan L, Tolwani A, Heung M, Szamosfalvi B, et al. Troubleshooting Ionized Hypocalcemia in Patients on Continuous KRT with Regional Citrate Anticoagulation Kidney360, 2026.PMID 41201866
- [40]Parienti JJ, Mongardon N, Mégarbane B, Mira JP, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site N Engl J Med, 2015.PMID 26398070
- [41]Yadava D, Tripathi M, Rai S, Malviya D, et al. A study of citrate and bivalirudin for anticoagulation during continuous renal replacement therapy in critically ill patients with acute kidney injury Saudi J Anaesth, 2026.PMID 41710639
- [42]Forsal I, Pouchoulin D, Roos V, Echeverri J, et al. Net buffer load during regional citrate anticoagulated continuous renal replacement therapy PLoS One, 2025.PMID 39883646
- [43]Hu C, Shui P, Zhang B, Xu X, et al. How to safeguard the continuous renal replacement therapy circuit: a narrative review Front Med (Lausanne), 2024.PMID 39234046
- [44]Kameda S, Fujii T, Ikeda J, Kageyama A, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study BMC Nephrol, 2023.PMID 36642717